Alzheimer's disease

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for...

Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a report on gov.ie, a central portal for government services and information. The plant itself will employ more than 300 once it's complete....

The FDA has placed a clinical hold on Cortexyme Inc's (NASDAQ: CRTX) atuzaginstat (COR388) Investigational New Drug application (IND 134303).  The Company plans to provide additional updates pending continued engagement with FDA. Cortexyme is immediately implementing a...

The FDA has issued a clinical hold on Denali Therapeutics Inc's (NASDAQ: DNLI) Investigational New Drug (IND) application for DNL919 (ATV:TREM2). TREM2 is a protein expressed in microglia, the brain's resident immune cells.  Mutations in the TREM2 gene are strongly...

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia.  However, the decision only...

Longeveron Inc (NASDAQ: LGVN) has initiated its Phase 2a clinical trial evaluating Lomecel-B for Alzheimer’s disease (AD). The first patient has consented to participate in the trial, and patient screening has begun. What Happened: The Phase 2a study intends to build on encouraging...

Hoth Therapeutics Inc (NASDAQ: HOTH) announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.  HT-ALZ is in development under the 505(b)(2) regulatory pathway for the treatment of dementia-related to...

Federal officials are struggling with a decision that could determine the future of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm, and whether significant numbers of patients use it. In January, Medicare plans to issue a preliminary decision on covering the expensive...

After suffering rejection from the FDA in April, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is making another bid to expand the scope of its Parkinson's disease med Nuplazid. Acadia plans to resubmit its application for Nuplazid (pimavanserin) to treat hallucinations...

In a surprise move, Biogen Inc (NASDAQ: BIIB) announced that it would slash the price of its controversial Alzheimer's drug Aduhelm in half from $56,000 to $28,000. In Q3, Biogen generated a mere 300k from Aduhelm sales, indicating that less than 100 Alzheimer's...

Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determine the pharmacokinetics, safety, and tolerability of AL001 and target doses for...

The European Medicines Agency has recommended the European Commission to reject Biogen Inc's (NASDAQ: BIIB) Aduhelm, an expected blow to its hopes of finding a widespread market for its struggling Alzheimer's drug. The EMA recommendation had been expected since the EMA's...

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s disease drug Aduhelm out in four years.  The companies will launch a global 1,300-person trial in May 2022 that...

Between slow sales, safety concerns, and possible European rejection for Alzheimer's disease drug Aduhelm, Biogen Inc (NASDAQ: BIIB) is planning large-scale layoffs, STAT News reports, citing a Biogen employee close to the matter.  The publication writes that the plan has...

From the Cleveland Clinic, one of the teams reports it has found a potential Alzheimer’s treatment in one of the world’s most famous drugs - Pfizer Inc’s (NYSE: PFE) erectile dysfunction treatment Viagra (sildenafil). The Cleveland Clinic researchers screened a database...